Brief: DAWNZERA Receives Positive Opinion From CHMP, Recommended For Approval In EU For Hereditary Angioedema
14/11/2025 12:01
Nov 14 (Reuters) - Ionis Pharmaceuticals Inc IONS.O: DAWNZERA™(DONIDALORSEN) RECEIVES POSITIVE OPINION FROM CHMP, RECOMMENDED FOR APPROVAL IN EU FOR HEREDITARY ANGIOEDEMA (HAE) IONIS PHARMACEUTICALS INC - EUROPEAN COMMISSION DECISION EXPECTED IN Q1 2026 Source text: ID:nBwbmWzh1a Further company coverage: IONS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ionis Pharmaceuticals
See all newsAnalysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
Brief: Ionis Announces License Agreement With Recordati For Zilganersen In Alexander Disease (Axd) In All Countries Outside The U.S.
Brief: Ionis Pharmaceuticals Says FDA Approved Tryngolza For Severe Hypertriglyceridemia
Brief: FDA Approves Treatment To Reduce Risk Of Acute Pancreatitis In Adults With Severe Hypertriglyceridemia
Brief: Ionis Announces Appointment Of Ludwig Hantson, Ph.D. To Board Of Directors